Bausch Health Completes $63 Mln Acquisition Of DURECT, Adds Breakthrough AH Therapy

Bausch Health Companies Inc. has finalized its tender offer to acquire DURECT Corporation for $1.75 per share in cash, an upfront payment of approximately $63 million, augmented by up to $350 million in potential sales-based milestone payments. This strategic acquisition integrates larsucosterol, DURECT's lead asset with FDA Breakthrough Therapy Designation for alcohol-associated hepatitis (AH)—a condition currently without approved therapies and a high mortality rate—into Bausch's hepatology pipeline, with a registrational Phase 3 trial planned. DURECT is now a wholly owned subsidiary of Bausch Health, and its shares have been delisted from Nasdaq.

Analysis

Bausch Health has strategically expanded its hepatology pipeline through the acquisition of DURECT Corporation, a deal structured with a modest $63 million upfront payment and a significant, performance-based upside of up to $350 million in milestone payments. The core asset acquired is larsucosterol, which targets alcohol-associated hepatitis (AH), a condition with a 30% 90-day mortality rate and no currently approved therapies. Larsucosterol’s FDA Breakthrough Therapy Designation signals a potentially expedited regulatory pathway, reinforcing the strategic value of the asset. This acquisition aligns with the company's stated R&D focus on addressing unmet needs in liver disease. The planned registrational Phase 3 trial for larsucosterol will be a critical catalyst, as the deal's ultimate financial success is heavily contingent on positive clinical outcomes and future sales.

Key Decisions for Investors

• For Bausch Health investors, this acquisition represents a calculated, long-term investment in its R&D pipeline, adding a late-stage asset with significant market potential in an area of high unmet medical need.
• Investors should closely monitor the progress and data from the upcoming Phase 3 trial of larsucosterol, as the realization of the deal's full value is overwhelmingly dependent on its clinical and commercial success.
• Former DURECT shareholders now holding contingent value rights should recognize their future returns are directly linked to Bausch Health's execution capabilities in bringing larsucosterol through final trials and to market.